Pharmacokinetic evaluation of fluvoxamine for the treatment of anxiety disorders.
BACKGROUND
Fluvoxamine is one of the most widely prescribed antidepressants and presents data from 30 years of clinical experience.


METHODS
The present review article describes the pharmacokinetic properties of fluvoxamine and their implications for the treatment of anxiety disorders (AD). A search in the main database sources (Medline, Isi Web of Knowledge and Medscape) has been performed in order to obtain a comprehensive and balanced evaluation of fluvoxamine about the implications of its pharmacokinetic properties for the treatment of AD. The word 'fluvoxamine' has been associated with 'pharmacokinetics', 'interactions', 'generalized anxiety disorder', 'social anxiety disorder', 'social phobia', 'panic disorder', 'anxiety' and 'tolerability'. No restriction criteria were established in relation to methodology or year of publication. Only English-language articles have been selected.


CONCLUSIONS
Fluvoxamine presents high tolerability and safety so that it can be considered as a therapeutic option in case of panic disorder and social anxiety disorder. In contrast, its weakness is in extended interaction with CYP450 enzymatic system that may limit its use in elderly or patients with medical comorbidities. Finally, data of efficacy about generalized anxiety disorder are very limited and preliminary so that it is not possible to draw any sound conclusions.
University of Milan, Department of Psychiatry, Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico , via Francesco Sforza 35, 20122, Milan , Italy massimiliano.buoli@hotmail.it.
Alfredo Carlo
AC
Altamura
Alice
A
Caldiroli
Massimiliano
M
Buoli
D000368:Aged; D000818:Animals; D014151:Anti-Anxiety Agents / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001008:Anxiety Disorders / Q000188:drug therapy* / Q000503:physiopathology; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D016666:Fluvoxamine / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D006801:Humans
D014151:Anti-Anxiety Agents; D003577:Cytochrome P-450 Enzyme System; D016666:Fluvoxamine
anxiety disorder; fluvoxamine; pharmacokinetics